Revolutionizing Dermatology: Embracing GLP-1 Treatments, Elevating Chronic Spontaneous Urticaria Management, and Broadening Patient Accessibility
Picture this: You step into a patient's room, confronted by widespread psoriasis patches on their skin, and you notice they're carrying extra weight. Suddenly, it clicks – those fat cells aren't just innocent bystanders; they're fueling the very inflammation ravaging their skin. That's the eye-opening shift in dermatologic care we're diving into today, thanks to insights from Marc Serota, MD, at the 2025 Fall Clinical Dermatology Conference in Las Vegas (https://www.dermatologytimes.com/conference/fall-clinical-dermatology).
Serota, who wears multiple hats as a dermatologist, allergist-immunologist, pediatrician, and obesity medicine specialist at Epiphany Dermatology in Littleton, Colorado, illuminated the exciting crossovers in skin health. His talk covered how GLP-1 receptor agonists are transforming psoriasis care, how our grasp of chronic spontaneous urticaria (CSU) is evolving, and the emerging blend of care delivery methods setting the stage for 2026. But here's where it gets controversial – are dermatologists overstepping by tackling obesity, or is this the holistic approach skin patients desperately need?
Let's break down GLP-1 receptor agonists for beginners: These are medications that mimic a hormone called glucagon-like peptide-1, originally developed for diabetes and weight management. They work by slowing stomach emptying, reducing appetite, and helping the body regulate blood sugar. In dermatology, Serota explained, we must view obesity not as a simple weight issue, but as a persistent inflammatory state that worsens skin conditions like psoriasis. 'When a patient is overweight or obese, they should absolutely be considered for GLP-1 therapy, psoriasis or not,' Serota noted in an interview with Dermatology Times. 'And in our field, pairing these treatments leads to superior results.'
To understand why, imagine those enlarged fat cells: They become oxygen-starved and start dying, releasing harmful inflammatory substances called cytokines that ignite fires in the body and on the skin. GLP-1 drugs cut down on fat mass and these inflammatory signals, which not only aids weight loss but might also calm psoriasis flare-ups. Serota stressed a comprehensive strategy: 'By addressing both the metabolic roots and the skin symptoms, we're delivering top-tier care – benefiting their complexion and overall well-being in the long run.' And this is the part most people miss: It's not just about clear skin; it's about preventing heart disease or diabetes down the line, turning dermatology into a preventive powerhouse.
Now, shifting gears to CSU – and here's a twist that's sparking debate: This condition, once largely handed off to allergists, is making a comeback in dermatology offices. CSU involves chronic hives that pop up for no apparent reason, lasting over six weeks with each welt fading in under 24 hours. Instead of blaming external allergens, we now see it as an autoimmune or autoallergic process. 'Dermatologists can diagnose and manage this confidently now,' Serota shared. While injections like omalizumab have been the go-to, fresh options are shaking things up. Dupilumab, for instance, is FDA-approved for CSU, and remibrutinib – the first oral BTK inhibitor greenlit for this use (https://www.dermatologytimes.com/view/fda-approves-remibrutinib-first-oral-btk-inhibitor-for-csu) – provides another tool for control. 'Dermatologists are now equipped with targeted treatments they're eager to prescribe,' he added. But is this expansion of dermatology's scope a game-changer for patient convenience, or are we risking overlap with other specialists?
Looking forward to 2026, Serota is eyeing the evolution of how care is delivered. The COVID-19 pandemic fast-tracked telemedicine, but now we're striking a harmonious balance. 'Pharma firms, employers, and healthcare networks are teaming up to widen access to certified experts through virtual means,' he explained. This hybrid approach means routine check-ins and follow-ups can happen online, saving time and resources, while tricky procedures or severe cases still require face-to-face visits. 'It's not an either-or situation,' Serota emphasized. 'The big trend is a smart mix of both virtual and in-person care.' This could mean more inclusive dermatology for rural patients or those with mobility issues – but does it dilute the personal touch of traditional visits?
As we wrap up, ponder this: Should dermatologists broaden their roles to include metabolic health, or stick strictly to skin? And with hybrid care models rising, will quality of care suffer, or is this the future of efficient healthcare? We'd love to hear your take – agree or disagree in the comments below!
Newsletter
Enjoying this deep dive? Sign up for Dermatology Times newsletters to get weekly insights on cutting-edge treatments, groundbreaking innovations, and practical advice straight from the clinic.
